Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability. by Fowler, Christie D & Kenny, Paul J
UC Irvine
UC Irvine Previously Published Works
Title
Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence 
vulnerability.
Permalink
https://escholarship.org/uc/item/47x1d4p3
Authors
Fowler, Christie D
Kenny, Paul J
Publication Date
2014
DOI
10.1016/j.neuropharm.2013.09.008
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Nicotine aversion: Neurobiological mechanisms and
relevance to tobacco dependence vulnerability
Christie D. Fowler1,2 and Paul J. Kenny1,2
1Laboratory of Behavioral and Molecular Neuroscience, Department of
Molecular Therapeutics; 2Department of Neuroscience, The Scripps Research
Institute,
Jupiter, FL 33458, USA
Neuropharmacology
Running title: Nicotine aversion
Correspondence  should  be  addressed  to  Paul  Kenny,  Ph.D.,  Laboratory  of
Behavioral  and  Molecular  Neuroscience,  Department  of  Molecular
Therapeutics,  The  Scripps  Research  Institute  –  Florida,  130  Scripps  Way,
Jupiter, FL 33458, USA. Tel: (561) 228-2231; E-mail: pjkenny@scripps.edu
This work was supported by a grant from the National Institute on Drug Abuse
(DA020686  to  P.J.K.  and  DA032543  to  C.D.F.).  This  is  manuscript  number
23035 from The Scripps Research Institute. 
1
Nicotine  stimulates  brain  reward  circuitries,  most  prominently  the
mesocorticolimbic dopamine system, and this action is considered critical in
establishing  and  maintaining  the  tobacco  smoking  habit.  Compounds  that
attenuate  the  rewarding  effects  of  nicotine  are  considered  promising
therapeutic  candidates  for  tobacco  dependence,  although  many  of  these
drugs  have  off-target  effects  that  limit  their  translation  to  the  human
condition. Consequently, the neurobiological mechanisms of nicotine reward
are  the  subject  of  intense  investigation.  Nicotine  is  also  highly  noxious,
particularly  at  higher  doses,  and aversive  reactions  to  nicotine  after  initial
exposure can decrease the likelihood of developing a tobacco habit in many
first  time  smokers.  Nevertheless,  relatively  little  is  known  about  the
mechanisms of  nicotine  aversion.  The purpose of  this  review is  to present
recent  new  insights  into  the  neurobiological  mechanisms  that  regulate
avoidance of nicotine. First, the role of the mesocorticolimbic system, so often
associated with nicotine reward, in regulating nicotine aversion is highlighted.
Second,  genetic  variation  that  modifies  noxious  responses  to  nicotine  and
thereby influences vulnerability to tobacco dependence, in particular variation
in  the  CHRNA5-CHRNA3-CHRNB4 nicotinic  acetylcholine  receptor  (nAChR)
subunit  gene  cluster,  will  be  discussed.  Third,  the  role  of  the  habenular
complex in nicotine aversion,  primarily  medial habenular projections to the
interpeduncular  nucleus  (IPN)  but  also  lateral  habenular  projections  to
rostromedial tegmental nucleus (RMTg) and ventral tegmental area (VTA) are
reviewed. Forth, brain circuits that are enriched in nAChRs, but whose role in
nicotine avoidance has not yet been assessed, will be proposed. Finally, the
feasibility of developing novel therapeutic agents for tobacco dependence that
act not by blocking nicotine reward but by enhancing nicotine avoidance will
be considered. 
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Introduction
Nicotine is considered the major reinforcing component of tobacco responsible
for addiction in human smokers (Stolerman and Jarvis, 1995), and it has been
shown that humans, non-human primates and rodents  will  volitionally  self-
administer the drug (Corrigall and Coen, 1989; Goldberg et al., 1981; Harvey
et al., 2004; Watkins et al., 1999). Volitionally consumed nicotine is known to
stimulate activity in brain reward circuitries  (Kenny and Markou, 2006), with
this action considered central to the establishment and maintenance of the
tobacco habit in human smokers. It is important to note, however, that instead
of hedonic reactions, most smokers report their initial smoking experiences as
unpleasant.  This  reflects  the  fact  that  in  addition  to  its  rewarding  effects,
nicotine  is  also  highly  noxious.  Highlighting  this  dichotomous  nature  of
nicotine,  doses  of  the  drug  that  support  maximal  rates  of  responding  in
squirrel monkeys also induce marked symptoms of aversion, such as vomiting,
when the drug-taking  habit  is  being acquired.  Moreover,  monkeys work  to
avoid non-contingent delivery of intravenous nicotine infusions even though
they will work equally hard to obtain those same nicotine infusions when they
are available for contingent  delivery  (Goldberg and Spealman, 1982,  1983;
Goldberg et al., 1981; Goldberg et al., 1983; Spealman and Goldberg, 1982).
These aversive reactions to nicotine are important in the context of tobacco
dependence, as stronger aversive reactions to nicotine after initial exposure
are negatively correlated with the development of habitual tobacco use in first
time smokers (Sartor et al., 2010). 
Aversive responses to nicotine also appear to play key roles in determining the
overall amounts of tobacco smoke consumed and patterns of intake. Indeed,
when levels of nicotine contained in tobacco are varied, smokers are far more
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efficient at titrating their  intake downwards when consuming high-nicotine-
content  tobacco  to  avoid  noxious  effects  of  the  drug  (Henningfield  and
Goldberg, 1983a; Henningfield et al., 1986; Russell et al., 1975), than they are
at adjusting their intake upward to compensate for reduced nicotine in low-
content tobacco (Sutton et al., 1978). Hence, self-regulation of consumption to
avoid noxious  effects of  nicotine is  far  better  regulated that compensation
upwards to avoid a reduction in nicotine intake. Also consistent with a key role
for noxious nicotine effects in controlling tobacco consumption, a treatment
strategy previously employed to facilitate smoking cessation,  but no longer
typically  used  (Hajek and Stead,  2004),  is  to encourage smokers  to inhale
tobacco smoke more rapidly and deeply than usual. This results in aversive
reactions to nicotine, with this increased nicotine exposure from more rapid
consumption resulting in persistent suppression of intake (Norton and Barske,
1977).  It  is  likely,  therefore,  that  tolerance  to  the  unpleasant  effects  of
nicotine,  and learning to efficiently control  tobacco smoking to avoid these
effects,  must  develop  in  order  for  habitual  tobacco  use  to  be  established
(Russell,  1979). As such, it  is probable that discrete circuitries in the brain
respond  to  the  noxious  properties  of  nicotine  and  that  learning  to  titrate
patterns  of  tobacco  consumption  in  order  to  avoid  activation  of  these
circuitries plays a key role in the acquisition of smoking behavior. Indeed, the
nicotinic acetylcholine receptor antagonist mecamylamine has been shown to
block  both  the  rewarding  and  aversive  effects  of  nicotine,  delivered  by
intravenous infusions to human volunteers  (Lundahl et al., 2000), consistent
with  their  being  at  least  two  discrete  populations  of  nAChRs  with  each
regulating  either  rewarding  or  aversive  effects  of  the  drug.  Diminished
sensitivity of nicotine-related aversion systems in the brain is therefore likely
to  increase  vulnerability  to  develop  habitual  smoking.  As  such,  it  may  be
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possible to target such circuitries in brain to enhance the noxious properties of
nicotine  with  small  molecule  drugs,  offering  a  novel  treatment strategy to
facilitate lower levels of tobacco consumption, and perhaps increased ability
to cease tobacco smoking altogether.  Nevertheless, until  recently relatively
little was known about which circuits in the brain regulate nicotine aversion, in
sharp  contrast  to  our  burgeoning  knowledge  on  mechanisms  of  nicotine
reward.  Here,  we  summarize  much  of  the  current  knowledge  on  the
mechanisms of nicotine aversion.
The mesocorticolimbic system and nicotine aversion
As noted above, the reward-enhancing actions of nicotine are hypothesized to
play a key role in the establishment and maintenance of the tobacco habit in
human smokers  (Kenny  and  Markou,  2006).  The  reward-related  actions  of
nicotine are thought to be related to the stimulatory effects of the drug on
neuronal  nicotinic  acetylcholine  receptors  (nAChRs)  containing  α4  and  β2
subunits  (denoted α4β2* nAChRs),  particularly  those located in  the ventral
tegmental area (VTA) (Corrigall et al., 1992; Ikemoto et al., 2006a; Maskos et
al., 2005; Picciotto et al., 1998; Tapper et al., 2004). Indeed, nicotine-induced
activation  of  α4β2*  nAChRs  in  the  VTA  increases  forebrain  dopamine
transmission, most prominently in the shell region of the nucleus accumbens
(NAc), and this has been shown to contribute to the reinforcing properties of
the  drug in  laboratory  animals  (Iyaniwura  et  al.,  2001;  Nisell  et  al.,  1997;
Pontieri et al., 1996). Because of their central role in nicotine reinforcement,
α4β2*  nAChRs  are  considered  important  targets  for  the  development  of
smoking  cessation  agents.  Varenicline  (Chantix)  is  the  only  FDA-approved
smoking cessation agent that was rationally designed through traditional drug
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discovery and was developed as an α4β2* nAChR partial agonist  (Coe et al.,
2005; Dwoskin et al., 2009; Lerman et al., 2007; Reus et al., 2007). 
In addition to α4β2* nAChRs in VTA, accumulating evidence suggests that α7
nAChRs in this site may also play a role in nicotine reinforcement. Nicotine-
induced increases in glutamatergic transmission in the VTA is thought to occur
through  actions  at  both  α4β2*  and  α7  nAChRs,  leading  to  increases  in
mesoaccumbens  dopamine  transmission  and  regulation  of  nicotine  self-
administration behavior (Besson et al., 2012; Gao et al., 2010; Mansvelder and
McGehee,  2000;  Mao  et  al.,  2011;  Melis  et  al.,  2013;  Pons  et  al.,  2008;
Schilstrom et al., 2000). Supporting a key role for nicotine-induced increases
in  glutamatergic  transmission  in  the  VTA  with  nicotine  reinforcement,
blockade of local NMDA receptors profoundly decreases nicotine intake in rats
(Kenny et al., 2009b). Considering the well-established role for the VTA and
mesocorticolimbic  dopamine  transmission  in  regulating  the  reinforcing
properties of nicotine and other drugs of abuse, it is interesting to note that
accumulating  evidence  implicates  this  same  system  in  nicotine  aversion.
Lesions  of  cholinergic  innervation  of  the  VTA  arising  from  the
pedunculopontine tegmental nucleus (PPTg) blocked the expression of reward-
related behaviors in response to nicotine and rendered ‘rewarding’ doses of
nicotine aversive, reflected in increased avoidance of the drug  (Laviolette et
al., 2002).  Similarly, blockade of α7 nAChRs or NMDA receptors in the VTA
switched  the  effects  of  nicotine  from rewarding  to  aversive  (Kenny  et  al.,
2009b; Laviolette and van der Kooy, 2003b). Projections from the VTA into the
striatum  and  NAc  also  appear  to  be  influenced  by  nicotinic  signaling.
Presynaptic  nAChRs  directly  regulate  the  release  of  dopamine  from
dopaminergic terminals  (Rice and Cragg, 2004; Zhou et al., 2001), in which
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452 nAChR subtype regulates DA release in the dorsal caudate/putamen
and the  4623 nAChR is involved in the NAc core  (Exley et al., 2012). In
these regions, several subtypes of nAChRs have been identified, including the
4, 5, 6, 7, 2 and 3 (Exley et al., 2012; Marks et al., 1992; Seguela et al.,
1993; Wada et al., 1989), and as such, nicotine has the potential to directly
and/or  indirectly  modulate  various  types  of  neurotransmission.  An intricate
network  of  cholinergic  interneurons  is  present  throughout  the  NAc  and
striatum. In addition to releasing acetylcholine, these interneurons may also
corelease glutamate  (Higley  et  al.,  2011).  Presynaptic  42*  nAChRs  have
been shown to enhance GABA release from inhibitory interneurons, which may
subsequently inhibit the cholinergic interneurons (Grilli et al., 2009; Koos and
Tepper, 2002; Sullivan et al., 2008). Increased accumbal acetylcholine release
is found during expression of a conditioned taste aversion (Mark et al., 1995),
and pharmacologically enhancing cholinergic signaling in the NAc is sufficient
to  produce  a  conditioned  taste  aversion  (Taylor  et  al.,  2011).  It  has  been
proposed that dopamine and acetylcholine act in an opposing manner within
the  NAc,  in  which  dopamine  mediates  reward-related  processing,  whereas
acetylcholine signals aversion-related events (Hoebel et al., 2007). Support for
this hypothesis derives from the findings that drugs of abuse, such as nicotine,
stimulate mesolimbic dopamine release (Mifsud et al., 1989), and in contrast,
increased acetylcholine  in  the  NAc attenuates  drug self-administration  and
promotes  escape  behavior  (Glowa  et  al.,  1997;  Rada  and  Hoebel,  2001;
Williams  and  Adinoff,  2008).  Furthermore,  nicotine  withdrawal  elicits  a
decrease  in  dopaminergic  signaling  that  is  paralleled  by  an  increase  in
acetylcholine (Rada et al., 2001). Although evidence supports this concept of
dopamine/acetylcholine  opponent  processing,  more  recent  findings  suggest
that acetylcholine can directly enhance dopamine release in this brain region
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as well  (Cachope et al.,  2012; Threlfell  et al., 2012). Moreover, rather than
diminishing its rewarding effects, blockade of dopamine receptors can in some
instances enhance the rewarding effects of nicotine, as measured using place
conditioning procedures  (Grieder et al.,  2012; Laviolette and van der Kooy,
2003a). Laviolette and colleagues have shown that blockade of dopamine D2
receptors in the shell region of the nucleus accumbens (NAc), or D1 receptors
in  the  core  region  of  the  accumbens,  can  switch  the  effects  of  intra-VTA
infusions of higher doses of nicotine from aversive to rewarding during place
conditioning  (Laviolette  et  al.,  2008).  Clarke  and co-workers  have similarly
shown that lesioning dopamine inputs to the NAc shell, achieved using local
infusions of the toxin 6-hydroxydopamine, abolished the rewarding effects of
intravenously delivered nicotine infusions  (Sellings et al., 2008). Conversely,
lesions of dopamine inputs into the NAc core region increased the rewarding
effects and abolished the aversion-related responses to nicotine, as measured
by conditioned taste aversion  (Sellings et al., 2008). These findings suggest
that dopamine signaling, at least somewhat compartmentalized between the
NAc shell  and core regions,  regulate the rewarding and aversive effects of
nicotine, respectively.  
One may question how mesoaccumbens dopamine transmission can be critical
for both the reinforcing properties of nicotine that support consumption of the
drug and also the aversive effects of the drug that support avoidance? Two
recent findings appear to shed important light on this issue. First, Malenka and
colleagues have shown that  distinct  populations  of  VTA dopamine neurons
may separately encode reward-related and aversion-related information, and
thus  guide  approach or  avoidance behaviors  accordingly.  Specifically,  they
found that the cholinergic inputs to the VTA from the laterodorsal tegmental
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nucleus  (LDTg),  and  inputs  to  the  VTA  from  the  lateral  habenula  (LHb),
regulate reward and aversion behaviors in mice, respectively (Lammel et al.,
2012). Moreover, LDTg neurons preferentially synapse onto dopamine neurons
that project to the NAc shell, whereas LHb neurons synapse onto dopamine
neurons  that  project  to  the  medial  prefrontal  cortex  or  the  rostromedial
tegmental  nucleus  (RMTg),  both  areas  of  the  brain  involved  in  response
suppression (Lammel et al., 2012). Hence, these findings are consistent with
the  concept  that  discrete  populations  of  dopamine  neurons  receive
information from brain regions that regulate appetitive or aversive responses,
which in  turn project  to discrete areas of  the accumbens (and other brain
sites) to regulate approach versus avoidance behaviors. Consistent with this
possibility,  Suto  and  Wise  have  shown  recently  that  enhancing  dopamine
transmission by co-infusion of a D1 and a D2 receptor agonist in the NAc core,
but  not  shell,  increased  satiety-like  responses  to  intravenously  self-
administered cocaine infusions  (Suto and Wise, 2011); see also  (Suto et al.,
2009; Suto et al., 2010).  
In addition to dopamine and acetylcholine, opioid signaling also appears to be
an important mediator of aversive processing within the NAc, most notably
through the kappa opioid receptor (KOR) (McCutcheon et al., 2012; Resendez
et al., 2012), and interactions between nicotinic and KOR signaling have been
established.  Administration  of  KOR agonists  can attenuate nicotine-induced
hyperlocomotion in rats (Hahn et al., 2000), and chronic nicotine pretreatment
can enhance the effectiveness of KOR agonists to induce a place aversion or
anxiolytic-like response in adult rats  (Tejeda et al., 2012). Following chronic
nicotine  exposure,  the  somatic  signs  of  nicotine  withdrawal  may  also  be
potentiated  by  KOR  activation,  an  effect  that  can  be  reversed  by  co-
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administration of  the KOR antagonist,  nor-BNI  (Tejeda et al.,  2012).  At the
intracellular  level,  it  is  an  interesting  possibility  that  nicotine  signaling  in
accumbens  may  exert  its  aversive  effects  by  stimulating  cAMP  signaling
cascades,  resulting in activation of  cAMP response element-binding protein
(CREB) and consequently the increased transcription of the endogenous KOR
ligand, dynorphin (McCarthy et al., 2012). Taken together, the above findings
suggest  that  neurotransmission  in  the  NAc  shell  regulates  the  reinforcing
effects  of  nicotine  and other  drugs  of  abuse that  drive  their  consumption.
Conversely,  the  NAc  core  may  regulate  satiety  responses  and  avoidance
behaviors that limit consumption of nicotine and other addictive drugs.
 
Genetics of tobacco dependence and nicotine aversion
In mice, it has been shown that genetic factors play a key role in regulating
sensitivity  to  the  aversive  effects  of  nicotine  (Risinger  and  Brown,  1996).
Emerging data from genome-wide association studies (GWAS) are identifying
polymorphisms that increase vulnerability to tobacco dependence in humans,
and  also  support  the  notion  that  sensitivity  to  nicotine  aversion  may  be
influenced by genetics. A prominent gene in which allelic variation has been
associated with risk of developing tobacco dependence is CYP2A6. This gene
encodes  the  cytochrome  P450  enzyme  responsible  for  ~80%  of  nicotine
metabolism in the human liver  (Raunio and Rahnasto-Rilla, 2012; Ray et al.,
2009; Thorgeirsson et al., 2010). CYP2A6 polymorphisms are more commonly
found  in  individuals  of  Asian  descent  and  less  frequently  in  Caucasians
(Johansson  and  Ingelman-Sundberg,  2011).  The  CYP2A6 gene  is  highly
polymorphic,  with over 60 allelic  variants known. Of these, 17 alleles have
been shown to exhibit reduced function, whereas two of the variants result in
increased  nicotine  metabolism  (Mwenifumbo  et  al.,  2008;  Raunio  and
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Rahnasto-Rilla,  2012).  Allelic  variations  that  result  in  a  slower  metabolism
would be expected to allow for a more prolonged action of nicotine. As such,
nicotine  clearance  is  expected  to  be  decreased  and  doses  required  to
experience the rewarding and aversive effects of  the drug would be lower
(e.g.,  leftward  shift  of  the  dose-response  curve).  Consistent  with  this
prediction,  individuals  with  a  slow  metabolizer  CYP2A6 genotype  are  less
vulnerable  to  develop  tobacco  dependence  than  those  with  normal
metabolism (Audrain-McGovern et al., 2007; Bloom et al., 2011; Thorgeirsson
et  al.,  2010),  potentially  due  to  a  greater  aversive  response  when similar
amounts of nicotine are consumed. In further support of this notion, the slow
metabolizers  intake  less  nicotine  per  day  and  are  more  successful  when
attempting  to  quit  smoking  than  individuals  with  a  normal  metabolism
(Patterson et al., 2008; Rodriguez et al., 2011; Strasser et al., 2007). Thus, a
slower metabolism permits smaller quantities of the drug to be consumed that
lead to prolonged activity at nAChRs. As such, it may be more difficult for the
individual behaviorally titrate their intake to avoid synaptic accumulation and
subsequent activation of lower affinity nAChRs involved in aversive signaling
(see nAChR subtype discussion below). In  contrast,  faster rates  of  nicotine
metabolism would  allow for  quicker  recovery  from the  actions  of  nicotine,
resulting in diminished sensitivity to the aversive effects of the drug. Indeed,
individuals that rapidly metabolize nicotine exhibit lower cessation rates and
more severe withdrawal symptoms (Bloom et al., 2011; Patterson et al., 2008).
Given that both withdrawal duration and severity predict likelihood to relapse
(Piasecki et al., 2000), the aversive state elicited during nicotine withdrawal
likely motivates the individual to seek and continue to consume the drug, thus
maintaining the tobacco smoking habit.  Interestingly,  metabolism regulated
by CYP2A6 may be directly modulated by tobacco exposure and contribute to
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the  development  of  dependence.  Smokers  exhibit  a  slower  clearance  of
nicotine  compared  to  non-smokers  (Hukkanen  et  al.,  2005),  and  nicotine
appears to reduce CYP2A6 transcript and protein levels in monkeys (Ferguson
et al., 2012; Schoedel et al., 2003). Finally, given that the CYP2A6 gene is also
expressed  in  respiratory  tissues,  it  is  perhaps  not  surprising  that  CYP2A6
allelic  variation is  associated with smoking-related diseases,  such as COPD
and cancer  (Ariyoshi et al.,  2002; Hukkanen et al., 2002; Wassenaar et al.,
2011).
Insert Fig. 1 about here
Since the main site of action of nicotine in the brain is the nAChRs, it may be
expected  that  genetic  variation  in  the  genes  encoding  nAChR  receptor
subunits would be implicated in tobacco dependence vulnerability. However,
what may be surprising is the fact that the subunit genes most implicated in
dependence vulnerability are not those that encode the high-affinity nAChRs
responsible for regulating the rewarding effects of nicotine (42* nAChRs),
but instead lesser studies  5,  3 and  4 nAChRs nAChR subunit genes best
known  for  their  role  in  regulating  ganglionic  nAChR  transmission  (Fig.  1).
Indeed,  recent  GWAS  studies  have  shown  that  variation  in  the  CHRNA3-
CHRNA5-CHRNAB4 gene  cluster,  which  encodes  the  3,  5  and  4 nAChR
receptor subunits, respectively, is prominently associated with predisposition
to develop tobacco dependence. Variation in this  cluster is  also associated
with  vulnerability  to  many  smoking-associated  diseases  such  as  chronic
obstructive pulmonary disease (COPD) and lung cancer  (Bierut et al.,  2008;
Hung et al., 2008; Saccone et al., 2010; Saccone et al., 2007; Thorgeirsson et
al., 2008).  Strikingly, the risk of developing tobacco dependence appears to
be more than doubled in individuals carrying two copies of the  CHRNA5 risk
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allele,  rs16969968,  a  polymorphism  that  results  in  an  aspartic  acid  to
asparagine substitution at amino acid residue 398 (D398N). The D398N risk
variant is also associated with early onset of smoking behavior  (Weiss et al.,
2008),  a  self-reported  “pleasurable  buzz”  during  smoking  (Sherva  et  al.,
2008), and heavy smoking (Berrettini et al., 2008; Bierut et al., 2008; Grucza
et  al.,  2008;  Stevens  et  al.,  2008).  As  described  in  detail  below,  genetic
variation  in  the  CHRNA5-CHRNA3-CHRNB4 subunit  cluster,  and  resultant
alterations  in  the  function  of  mature  nAChRs  incorporating  these  altered
subunits,  appears  to  regulate  tobacco  dependence  vulnerability  not  by
altering  the  stimulatory  effects  of  nicotine  on  brain  reward  systems,  but
instead by diminishing the aversive effects of nicotine.
The CHRNA5-CHRNA3-CHRNB3 gene cluster and nicotine aversion
Genetic  variation  in  enzymes  responsible  for  nicotine  metabolism  can
influence  tobacco  dependence  vulnerability  as  noted  above,  perhaps  by
regulating  sensitivity  to  the  aversive  effects  of  nicotine.  Considering  that
genetic variation in the  CHRNA5-CHRNA3-CHRNB4 gene cluster,  particularly
genetic variation that diminishes 5* nAChR activity, also influences tobacco
dependence vulnerability, our laboratory sought to determine if this effect was
because  of  enhanced  rewarding  effects  of  nicotine  or  instead  diminished
sensitivity the aversive properties of the drug.
Using  a  mouse  intravenous  nicotine  self-administration  procedure,  we
assessed nicotine intake in wild-type (WT) and 5 subunit knockout (KO) mice
on a C57BL6 background; for full details, see (Fowler et al., 2011). We found
that both genotypes responded for intravenous nicotine infusions according to
an inverted U-shaped dose-response (D-R) curve (Fig. 1). Levels of intake were
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similar between WT and KO mice when lower doses of nicotine were available.
The  ascending  portion  of  the  D-R  curve  is  thought  to  reflect  increasing
reinforcing properties of nicotine as the unit dose increases (Henningfield and
Goldberg, 1983b; Lynch and Carroll, 2001). Therefore, our data suggest that
the  rewarding  effects  of  nicotine  are  unaltered  by  α5  subunit  deletion.  In
contrast, strikingly different patterns of intake were revealed when higher unit
doses  of  nicotine  were  available,  with  the  KO  mice  responding  far  more
vigorously than WT mice (Fig. 1). In control experiments, it was shown that
this increased nicotine intake in KO mice was not secondary to alterations in
operant performance or alterations in sensitivity to drug or non-drug paired
conditioned stimuli.
When  we  examined  total  amounts  of  nicotine  consumed  at  each  dose
available in the WT and α5 KO mice, we found that WT mice consumed ~1.5
mg kg-1 per session independent of the available dose (Fig. 1). In contrast, KO
mice  consumed  progressively  greater  amounts  of  the  drug  as  the  dose
increased. This suggests that WT mice efficiently titrate their intake whereas
this  behavior  is  largely  absent  in  α5  subunit  KO  mice.  Similar  to  human
smokers,  diminished  responding  of  rodents  for  nicotine  as  the  unit  dose
increases  is  thought  to  reflect  greater  restraint  over  intake  to  avoid  the
increasingly aversive effects of the drug  (Henningfield and Goldberg, 1983b;
Lynch  and  Carroll,  2001).  As  such,  these  findings  suggest  that  diminished
aversive  effects  of  nicotine,  measured  by  increased  responding  on  the
descending  portion  of  the  D-R  curve  for  self-administered  nicotine,  likely
explains the increased nicotine intake in α5 KO mice see (Fowler et al., 2011)
and perhaps in  humans carrying  CHRNA5 risk  alleles  (Bierut  et  al.,  2008).
Consistent with these findings, it was also reported that high nicotine doses
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continued to support place-conditioning behavior in the knockout mice even
though these doses  were  no longer  rewarding in  WT mice  (Jackson et  al.,
2010).  While it is plausible that rodents vary in their aversive responses to
nicotine as compared to humans, the similarities between the findings in both
species  supports  the  notion  that  similar  aversive  states  underlie  nicotine’s
effects. The plasma concentrations achieved by self-administering WT mice
are comparable to those in humans after 5 hours of smoking their preferred
cigarette  (Fowler and Kenny, 2011; Fowler et al.,  2011; Matta et al.,  2007;
Russell et al., 1975). Moreover, self-administration of intravenous nicotine in
both  rodents  and  humans  decreases  when  higher  doses  of  the  drug  are
provided (Fowler and Kenny, 2011; Harvey et al., 2004), similar to that found
with  cigarette  smoking  in  humans  (Henningfield  and  Goldberg,  1983a;
Henningfield et al., 1986; Russell et al., 1975). These data, combined with the
findings that altered expression of the 5* nAChRs in mice, rats and humans
results in a similar behavior profile in relation to nicotine consumption, support
the contention that the aversion induced by nicotine is likely conserved across
species. Even so it  remains unclear what precise psychological  state(s) are
achieved with these high doses of nicotine, and while this type of assessment
may be more readily investigated in humans, it will likely remain unclear in
rodents  until  significant  advancements  are  achieved  in  assessing  rodent
psychological  states. In  addition  to  5*  nAChRs,  4*  nAChRs  also  play  an
important role in regulating the aversive properties of nicotine (Frahm et al.,
2011). Specifically, it was shown that transgenic overexpression of this subunit
in mice increased their sensitivity to the aversive properties of the drug and
consequently decreased nicotine drinking behavior  (Frahm et al., 2011). No
studies to date have reported the effects of genetic ablation or modification of
3 nAChR subunit expression on nicotine intake, likely because deletion of this
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subunit  results  in  post-natal  lethality.  Taken  together,  the  above  findings
suggest that the  CHRNA5-CHRNA3-CHRNB4 gene cluster plays a key role in
nicotine aversion but not nicotine reward, with genetic variation in this cluster
increasing vulnerability to tobacco dependence by attenuating the aversive
effects of nicotine and thereby diminishing avoidance of the drug.
The medial habenula-interpeduncular systems and nicotine aversion
The above findings show that disruption  of  α5* nAChR signaling increases,
whereas transgenic overexpression of  4 nAChR subunits decreases, nicotine
intake. These findings may appear counterintuitive when the role for nAChRs
in nicotine addiction has traditionally been to consider their involvement in
nicotine reward. Indeed, disruption of nAChR signaling, particularly the high-
affinity  nAChRs  (42*),  usually  results  in  diminished  reinforcing  effects  of
nicotine and consequently reduced consumption of the drug. Pharmacological
blockade of 42* nAChRs, or genetic disruption of 2 nAChR subunits, almost
invariably decreases nicotine intake in rats and mice  (Corrigall et al., 1994;
Corrigall et al., 1999; Corrigall et al., 2000; David et al., 2006; Ikemoto et al.,
2006b;  Kenny  et  al.,  2009a;  Maskos  et  al.,  2005;  Molles  et  al.,  2006).
Disruption of nAChR function in midbrain dopamine systems, particularly the
VTA,  is  generally  thought  to  be  responsible  for  the  decreased  reinforcing
effects of nicotine reported in these studies. In light of these previous studies,
it  is  somewhat  paradoxical  that  genetic  ablation  of  5*  nAChR  signaling
increases nicotine intake in rats and mice. Hence, these findings suggest that
5* nAChR receptors, and perhaps also 3* and 4* nAChRs, regulate nicotine
intake in  a  manner  distinctly  different  from nAChRs  in  midbrain  dopamine
systems. 
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The  5 nAChR subunit mRNA is expressed in the VTA and substantia nigra
pars compacta (SNc), as well as in deep layers of the cortex. However, the 5
nAChR  subunit  mRNA  is  most  densely  expressed  in  the  medial  habenula-
interpeduncular  nucleus  (IPN)  system  (Marks  et  al.,  1992).  The  3  and  4
subunits  are  also  predominately  found  in  the  MHb-IPN  system.  The  MHb
projects  almost  exclusively  to  the  IPN  via  the  fasciculus  retroflexus  (Fr)
(Herkenham and Nauta, 1979). Functional α5* nAChRs are expressed on MHb
afferents to IPN  (Grady et al., 2009; Sheffield et al., 2000). Intriguingly, the
MHb-IPN tract is known to limit consumption of noxious substances (Donovick
et al., 1970; Thornton et al., 1994) and regulate avoidance of aversive stimuli
(Donovick et al., 1970; Hammer and Klingberg, 1990; Meszaros et al., 1985;
Thompson, 1960; Thornton et al., 1994; Wirtshafter, 1981). This system is also
involved  in  the  expression  of  somatic  aspects  of  the  nicotine  withdrawal
syndrome  (Salas et al., 2009). We therefore hypothesized that α5* nAChRs,
and perhaps 3* and 4* nAChRs, in the MHb-IPN regulate aversive effects of
nicotine.  Consistent  with this  hypothesis,  we found that  virus-mediated re-
expression of the otherwise absent α5 subunit in the MHb-IPN system of the
KO mice completely rescued their behavioral phenotype; these “rescued” 5
KO mice reduced their level of nicotine intake at higher doses consistent with
the  behavioral  profile  exhibited  by  WT  mice.  Conversely,  virus-mediated
knockdown of this subunit in the MHb-IPN system of rats resulted in greater
intake,  particularly  when  high  unit  doses  of  the  drug  were  available  for
consumption  (Fowler et al., 2011). These findings suggest that the  CHRNA5-
CHRNA3-CHRNB4 gene cluster in the MHb-IPN system, and nAChRs in these
sites  that  incorporate  the  subunits  encoded  by  these  genes,  regulate  the
aversive effects of  higher nicotine doses that serve to suppress intake.  To
more directly test this hypothesis, we have examined the effects of nicotine on
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intracranial self-stimulation (ICSS) thresholds in  5 KO mice and in rats after
knockdown of 5 subunits in the MHb-IPN system. Nicotine-mediated lowering
of ICSS thresholds are thought to reflect the stimulatory actions of the drug on
the brain  reward systems responsible  for  establishing and maintaining  the
nicotine-taking habit in rodents and perhaps human tobacco smokers (Kenny,
2007). Conversely, elevations of ICSS thresholds induced by higher nicotine
doses are thought to reflect an inhibitory action on brain reward systems that
drives  avoidance of  the  drug  (Fowler  et  al.,  2011).   We found that  global
deletion of  5 nAChR subunits in the knockout mice  (Fowler et al., 2013), or
restricted knockdown of the subunits in the MHb-IPN system of rats, abolished
the ICSS threshold-elevating effects of higher doses of nicotine but did not
impact the threshold-lowering effects of lower nicotine doses. The specific role
for α5* nAChRs in nicotine aversion but not nicotine reward may explain the
shape of the D-R curve for nicotine self-administration in humans, primates
and rodents, and why it is altered by  5* nAChR deficiency. Specifically, we
propose that nicotine reward and aversion are dissociable effects, with the
mesoaccumbens  dopamine  neurons  that  project  to  the  accumbens  shell
region likely playing an important role in the positive reinforcing effects of
nicotine,  and  the  habenula-interpeduncular  systems  regulating  nicotine
aversion. The rewarding actions of nicotine may occur through the α4α623*
nAChR  subtype  (Grady  et  al.,  2007),  which  has  the  highest  sensitivity  to
nicotine of any native nAChR so far identified (Grady et al., 2007) and would
explain the “ascending” portion of the D-R curve. As α6nAChR subunits are
not expressed in the MHb-IPN aversion pathway, the high-affinity α4α623
nAChR  subtype  is  not  expressed  locally.  Instead,  nicotine  activates  this
pathway through lower affinity α5* nAChRs, accounting for  the descending
portion of the D-R curve at higher nicotine doses. The combinatorial effects of
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nicotine  at  the  high-affinity  α4α623*  nAChRs  in  the  mesoaccumbens
systems,  and  lower  affinity  α5*  nAChRs  in  the  MHb-IPN  therefore  likely
explains  the  “window”  of  nicotine  doses  that  are  reinforcing,  and  the
emergence of aversion at higher doses resulting in a U-shaped dose-response
curve. Taking all the above data together, it seems that nicotine stimulates
the  MHb-IPN  pathway  through  α5*  nAChRs  and  thereby  enhances
glutamatergic  transmission  in,  and consequent  activation  of,  the IPN.  Most
available  smoking  cessation  agents  are  thought  to  attenuate  smoking
behavior  by  targeting  nAChRs  in  midbrain  dopamine  systems,  perhaps  by
targeting the α4α623* nAChRs. As discussed below, it may be possible to
rationally  design  new  smoking  cessation  agents  that  act  independent  of
nicotine  reward  and  instead  act  by  targeting  α5*  nAChRs  in  habenular
aversion systems.  
Finally, almost exclusively, regions of the posterior septum are responsible for
providing  afferent  input  to  the  MHb.  Specifically,  the  triangular  septal  and
septofimbrial nuclei  and the bed nucleus of  the anterior  commissure (BAC)
densely innervate the MHb (Yamaguchi et al., 2013). Interestingly, lesions to
the septum or the interpeduncular nucleus can abolish aversive responses to,
and avoidance of,  noxious bitter  tastants such as quinine  (Donovick et al.,
1970).  This  suggests  that  major  functions  of  the  septo-habenulo-
interpeduncular pathway include regulation of food consumption by controlling
avoidance of noxious substances. Interestingly, individuals with deficits in the
ability to detect bitter tastants are much more likely to be regular smokers
(Saper  et  al.,  2002).  Hence,  it  is  an  intriguing  possibility  that  constitutive
deficits  in  septo-habenulo-interpeduncular  function,  reflected  in  diminished
ability to detect bitter tastes, may also result in diminished sensitivity to the
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aversive  effects  of  nicotine  and  account  for  the  increased  vulnerability  to
developing  tobacco  dependence  in  such  individuals.  More  recently,  it  was
shown that septal inputs to MHb may also regulate anxiety and fear-related
behaviors in rodents  (Yamaguchi et al.,  2013). It  is  therefore interesting to
speculate  that  mood-regulated  effects  mediated  by  the  septo-habenulo-
interpeduncular  system  may  also  influence  vulnerability  to  tobacco
dependence. 
The  lateral  habenula-rostromedial  tegmental  area  pathway  and
nicotine aversion
In addition to the MHb projection to the IPN, recent evidence suggests that the
lateral habenula (LHb) may also play a role in nicotine aversion. Unlike the
MHb, which projects almost exclusively to IPN, the LHb projects only sparely to
IPN and instead sends prominent projections to the rostromedial tegmental
nucleus (RMTg)  (Jhou et al., 2009), and less prominent projects to the VTA.
Through these projections, the LHb inhibits the firing of midbrain dopamine
neurons  directly  (via  VTA  projections)  or  indirectly  (via  RMTg  projections)
(Bromberg-Martin  and  Hikosaka,  2011;  Hikosaka,  2010;  Jhou  et  al.,  2009;
Lecourtier and Kelly, 2007; Matsumoto and Hikosaka, 2009). LHb neurons are
activated by aversive stimuli or omission of anticipated rewards  (Bromberg-
Martin  and  Hikosaka,  2011;  Hikosaka,  2010;  Lecourtier  and  Kelly,  2007;
Matsumoto and Hikosaka, 2009). This suggests that LHb transmission, and its
inputs  to  RMTg,  could  encode  aspects  of  nicotine  aversion  and  influence
responses to the drug. Consistent with this possibility, Pistis and colleagues
have recently shown that nicotine potently and robustly excites neurons in the
RMTg (Lecca et al., 2012). This effect was likely related to a stimulatory action
of nicotine on α7 nAChRs located presynaptically on excitatory glutamatergic
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inputs from the LHb  (Lecca et al.,  2012). The functional consequent of this
stimulatory  effect  of  nicotine  on  RMTg  transmission  in  regulating  nicotine
aversion and nicotine consumption has not been directly investigated.
Other brain circuitries that may play a role in nicotine aversion
As  described  above,  the  MHb-IPN  system  densely  expresses  nAChRs
containing  α5,  α3  and/or  4  subunits.  Indeed,  it  was  based  on  the  dense
expression  of  these  subunits  in  the  MHb-IPN  system that  the  role  of  α5*
nAChRs  in  these  sites  in  nicotine  aversion  was  first  investigated  in  mice
(Fowler et al.,  2011). Interestingly,  the nucleus tractus solitarius (NTS) is a
hindbrain site that also displays very dense expression of these subunits. The
NTS contains at least three types of neurons: catecholaminergic neurons that
produce  the  neurotransmitter  norepinephrine  (and  to  a  lesser  extent
epinephrine);  glucagon-producing neurons that synthesize the neuropeptide
glucagon-like  peptide-1  (GLP-1);  and  neurons  that  synthesize  the  feeding-
related neuropeptide proopiomelanocortin (POMC). The NTS is perhaps best
known  for  its  role  in  regulating  taste  reactivity,  as  it  receives  dense
innervation from the buccal cavity  (Appleyard et al.,  2005; Grill  and Hayes,
2009).  NTS  neurons  also  receive  vagal  inputs  from  the  viscera  and  NTS
activation in response to vagal stimulation can induce cessation of food intake.
Specifically, catecholaminergic neurons relay signals to higher feeding centers
in the brain from the gastrointestinal (GI) tract related to meal ingestion or
gastric  distension,  and respond also  to  circulating  satiety  signals  including
cholecystokinin (CCK) (Appleyard et al., 2007; Monnikes et al., 1997; Rinaman
et al., 1998; Willing and Berthoud, 1997). Catecholaminergic neurons in the
NTS  have  been  implicated  in  the  expression  of  aversive  aspects  of  drug
withdrawal  (Delfs et al.,  2000; Taylor et al.,  1998). It  has been shown that
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nicotine  can  activate  NTS  catecholaminergic  neurons,  likely  though  a
mechanism involving increased local glutamatergic transmission (Feng et al.,
2012; Hong et al., 2012; Kalappa et al., 2011; Shiraki et al., 1997; Zhao et al.,
2007).  Moreover,  the   and   adrenergic  receptor  antagonist  carvedilol  can
reduce self-reported aversive responses to nicotine, delivered as a lozenge to
human volunteers (Sofuoglu et al., 2006). These findings suggest that nicotine
may  activate  NTS  catecholaminergic  neurons,  increasing  adrenergic
transmission  in  forebrain  regions,  with  this  effect  contributing  to  aversive
aspects  of  the  drug,  a  hypothesis  that  has  yet  to  be  tested.  NTS
catecholaminergic  neurons  have  instead  been  implicated  in  drug  reward
rather than aversion. Specifically, it was shown that the rewarding effects of
morphine are greatly diminished in dopamine β-hydroxylase knockout (DBH-
KO) mice that are unable to synthesize norepinephrine  (Olson et al., 2006),
and virus-mediated re-expression of DBH in the NTS of the KO mice restores
their  sensitivity  to  morphine  reward  (Olson  et  al.,  2006).  As  noted  above,
neurons that produce the neuropeptide GLP-1 are also a major population of
neurons  in  the  NTS.  Activation  of  GLP-1  occurs  in  response  to  gastric
distention, nausea, stress and illness and results in suppression of food intake
(Barrera et al., 2011; Hayes et al., 2009; Turton et al., 1996). Hence, the NTS,
and in particular GLP-1 neurons, seem well placed to regulate aversion-related
actions of  nicotine.  Nevertheless, the role of the NTS in nicotine avoidance
behavior has not yet been investigated.
Efferents of  the IPN are also of  interest as potential  mediators of  aversive
processing. Indeed, it is currently unknown how the MHb-IPN circuit integrates
aversion-related  information  with  the  reward-related  processing  of  the
mesocorticolimbic  pathway.  The  IPN  has  broad  ascending  and  descending
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projections to various brain regions. The most prominent of these projections
are  the  medial  septum/diagonal  band  of  Broca,  hippocampus,  dorsal
tegmental nucleus, raphe and periaqueductal gray (Groenewegen et al., 1986;
Klemm, 2004; Montone et al., 1988; Shibata and Suzuki, 1984). Many of these
regions, including the diagonal band of Broca, dorsal tegmental nucleus, and
raphe, send projections  to the VTA  (Groenewegen et al.,  1986;  Oades and
Halliday, 1987; Phillipson, 1979; Wirtshafter, 1981). Thus, MHb-IPN signaling
may  be  integrated  with  mesocorticolimbic  processing  via  an  intermediate
brain region that then projects to the VTA, similar to that found with the LHb-
RMTg-VTA circuit.  Thus, identification of the predominant neural circuit that
mediates a motivational response to consume, or cease consuming, nicotine
will be important to delineate in future investigations.
Novel smoking cessation agents that modulate nicotine aversion
Data  described  above  demonstrate  that  deficient  α5*  nAChR  signaling,
particularly in the MHb-IPN system, increases nicotine intake in rats and mice.
Hence,  an  intriguing  approach  to  facilitate  smoking  cessation  may be  the
development of small molecule compounds that amplify α5* nAChR signaling.
Before such selective compounds can be developed, it is critical to know which
subtype of α5* nAChRs regulates nicotine aversion. In heterologous expression
systems,  α5  subunits  can  co-assemble  into  α42,  α32,  and  α34  nAChR
subtypes  (Fucile  et  al.,  1997;  Gerzanich  et  al.,  1998;  Tapia  et  al.,  2007).
However, in the mammalian brain it appears that α5 subunits predominantly
assembles  into  α42*  nAChR subtypes  (Gotti  et  al.,  2007;  Kuryatov  et  al.,
2008; Mao et al., 2008; Perry et al., 2007). Indeed, using immunoprecipitation,
it was reported that α5 subunits are almost exclusively in complex with α42
subunits  in  the  hippocampus,  striatum,  cortex  and  thalamus,  with  almost
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undetectable levels of α3* nAChRs containing the α5 subunit in these regions
(Mao et al., 2008). In the MHb-IPN pathway ~11% of  2* nAChRs express α5
subunits  (Grady et al., 2009), whereas only ~5% of  4* nAChRs express the
subunit  (Grady  et  al.,  2009).  Importantly,  in  the  MHb-IPN  pathway  α34*
nAChRs are thought to exclusively regulate acetylcholine release (Grady et al.,
2009),  whereas  α42α5*  nAChRs  regulate  glutamate  release  (Girod  et  al.,
2000). We previously found that disruption of glutamatergic transmission in
the  IPN  increases  nicotine  intake  in  rats  in  a  manner  similar  to  genetic
disruption of α5* nAChR signaling in rats or mice (Fowler et al., 2011). Hence,
α42α5* nAChRs are likely  to be a functional  subtype in the MHb-IPN that
negatively  regulates nicotine  intake.  Boosting the activity  of  this  particular
nAChR subtype in response to nicotine consumption may therefore be a novel
strategy to decrease nicotine intake and facilitate smoking cessation efforts.
Nicotinic  receptors  are  pentameric  complexes  in  which  acetylcholine  (and
nicotine) binds at the interface between  and  subunits (orthosteric sites). It
is hypothesized that agonist binding at orthosteric sites stabilizes the receptor
channel  complex  in  the  “open”  conformation,  thereby  increasing  receptor
activity. Partial agonists less efficiently stabilize the receptor “open” state, and
conversely,  competitive  antagonists  stabilize  the  receptor  channel  in  the
“closed” state. Agonists may also stabilize a receptor transition from “active”
to  an  inactive  “desensitized”  state.  There  are  multiple  allosteric  sites
elsewhere on the multimeric  nAChR complex,  which by themselves do not
stimulate opening or closing of the receptor channel, but instead modify the
activity of the receptor once activated by orthosteric ligands (Changeux, 1990;
Changeux et al., 1984; Changeux et al., 1992; Chemouilli et al., 1985; Lena
and Changeux, 1993). Positive allosteric modulators (PAMs) are ligands that
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bind to allosteric sites to facilitate agonist-induced stabilization of the “open”
conformation  or  to  reduce  agonist-facilitated  receptor  desensitization,  with
PAMs  unable  to  influence  receptor  function  in  the  absence  of  orthosteric
agonists. Hence, PAMs can potentiate the stimulatory effects of low agonist
concentrations  on  nAChR  function  in  much  the  same  manner  that
benzodiazepines  potentiate  the  actions  of  GABA at  the  GABAA receptor.  A
number  of  features  of  PAM  acting  at  425*  suggest  that  they  may  be
particularly  attractive  candidates  as  novel  smoking  cessation  agents.  First,
because the  orthosteric  binding  site  is  so  well  conserved  between various
nAChR subtypes, it is difficult to engineer agonists with receptor selectivity
(Albrecht et al., 2008; Armishaw et al., 2009). Moreover, α5 nAChR subunits
co-expressed  with  β2  or  β4  subunits  do  not  co-assemble  into  functional
heteropentameric nAChRs without the presence of another  subunit (Boulter
et al.,  1987;  Couturier  et  al.,  1990).  Instead, α5 subunits  act as accessory
subunits that modulate receptor activation/desensitization kinetics  (Ramirez-
Latorre et al., 1996). Moreover, α5 subunits play a key role in generating novel
allosteric modulatory sites on α5* nAChRs (Taly et al., 2009). Thus, it is likely
to be far easier to develop PAMs that are highly selective for α4β2α5* nAChRs
compared to the development of orthosteric agonists. Second, it is expected
that α4β2α5* PAMs have low intrinsic activity at these nAChRs in the MHb-IPN
tract  or  other  brain  areas  (depending  on  cholinergic  tone).  Instead  PAMs
should potentiate α4β2α5* nAChRs most efficiently only  when activated by
nicotine in tobacco smoke. This is an important point when considering that
MHb-IPN activation typically occurs in response to aversive stimuli  (Donovick
et al., 1970; Hammer and Klingberg, 1990; Meszaros et al., 1985; Thompson,
1960; Thornton et al., 1994; Wirtshafter, 1981), suggesting that full α4β2α5*
nAChR agonists may possess intrinsic aversive properties that would limit their
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clinical utility. Furthermore, unlike orthosteric agonists, PAMs are unlikely to
desensitize and thereby inhibit α4β2α5* nAChRs. Desensitization of nAChRs by
full  agonists  could  paradoxically  decrease  MHb-IPN  sensitivity  to  nicotine,
resulting  in  an increase in  the  motivational  properties  of  the drug and an
undesired  increase  in  tobacco  consumption.   Finally,  by  potentiating  the
deficient  function  of  α4β2α5*  nAChRs  in  individuals  carrying  CHRNA5 risk
alleles,  PAMs  may  be  able  to  attenuate  genetic  vulnerability  to  tobacco
dependence.
In the context of developing α4β2α5* nAChR PAMs for smoking cessation, it is
interesting  to  note  that  that  the  acetylcholinesterase  (AChE)  inhibitors
galantamine and physostigmine are PAMs of α4β2* nAChRs  (Maelicke et al.,
2001;  Pereira  et  al.,  1994;  Pereira  et  al.,  1993;  Samochocki  et  al.,  2003;
Samochocki  et al.,  2000; Storch et al.,  1995), and codeine may also be an
α4β2* nAChR PAM (Storch et al., 1995). This action is not thought to be related
to  AChE  inhibitor  activity,  as  other  AChE  inhibitors  including  tacrine,
metrifonate, rivastigmine and donepezil do not share this action (Samochocki
et  al.,  2000).  Importantly,  the  FK1  monoclonal  antibody,  which  binds
selectively to α nAChR subunits (Schroder et al., 1994), completely abolishes
the PAM effects of galantamine, physostigmine and codeine on α4β2* nAChR
function  (Pereira et al., 1994; Storch et al., 1995), thereby verifying a direct
allosteric action on the α subunit, and not an orthosteric action at the interface
between    and    subunits.  Intriguingly,  a  recent  study  reported  that
galantamine is  a  PAM only  at  α4β2α5*  nAChRs,  and is  practically  inactive
α4β2*  nAChRs  that  do  not  contain  α5  subunits  (Kuryatov  et  al.,  2008).
Galantamine has been shown to reduce the number of cigarettes smoked in a
recent clinical trial  (Diehl et al., 2006) and also reduced intravenous nicotine
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self-administration  behavior  in  rats  (Hopkins  et  al.,  2012;  Liu  and Stewart,
2009). These actions of galantamine may be related in part to its PAM action
at α4β2α5* nAChRs. Nevertheless, galantamine is likely to have very limited
clinical  utility  for  smoking  cessation.  Its  PAM  action  occurs  only  at  low
concentrations, and at higher concentrations it inhibits α4β2α5* nAChRs. Also,
AChE inhibition by galantamine and other known PAMs is likely to be a major
confound. Therefore, it will be important to develop and test novel α5* nAChR
PAMs for smoking cessation that are efficacious across a broad dose-range
and are devoid of “off-target” effects. 
While the concept of enhancing nicotine aversion as a therapeutic strategy
may be novel, this type of approach has been used with other drugs of abuse,
such  as  alcohol.  Disulfiram  (Antabuse)  is  an  aversive  therapy  to  attain
abstinence  from  alcohol,  which  acts  by  irreversibly  inhibiting  an  enzyme
involved  in  alcohol  metabolism,  acetaldehyde  dehydrogenase  (Center  for
Substance Abuse Treatment,  2009).  During alcohol  consumption,  disulfiram
promotes the accumulation of acetaldehyde, resulting in moderate to severe
physical  reactions  that  include  nausea,  vomiting,  hypotension  and  facial
flushing. When alcohol  is  not consumed, side effects are minimal and may
include  headache  and  fatigue  (Fuller  and  Gordis,  2004).  The  clinical
effectiveness of disulfiram has been variable  (Brewer et al., 2000; Fuller and
Gordis, 2004), most notably due to issues with patient compliance (Suh et al.,
2006). While abstinence may be improved by promoting patient involvement
in support groups and extensive physician supervision  (Brewer et al., 2000),
treatment effectiveness can also be enhanced by concomitant use of other
therapeutics, such as acamprosate, a glutamate antagonist, or naltrexone, an
opioid receptor antagonist (Mason et al., 2006; Suh et al., 2006). Given these
27
considerations, a therapeutic that enhances the aversive effects of nicotine
may not be as straightforward as one would hope in the clinical setting due to
the potential confound of patient adherence to the dosing schedule. However,
compared to other drugs of abuse, nicotine’s aversive effects are more readily
induced,  as  evidenced  by  the  narrow  D-R  range  for  intake.  In  contrast,
aversive reactions to alcohol are usually minimal in the absence of disulfiram,
as evidenced by it being more readily consumed in excess. Thus, by choosing
to  not  take  disulfiram,  a  patient  with  alcoholism  may  largely  avoid  any
physiological aversion associated with alcohol consumption, whereas this will
be less likely with nicotine consumption. Nevertheless, treatments that include
physician supervision, support of family and friends, and education regarding
the severe and detrimental health consequences of continued tobacco use will
likely  be  more  effective  than  pharmacotherapies  alone.  Finally,  a  novel
‘aversion-inducing’ therapeutic for smoking cessation may be most efficacious
when used in conjunction with drugs that limit the rewarding properties of the
drug, such as Chantix. By concurrently enhancing the aversive while reducing
the rewarding properties of the drug, it is possible that long-term abstinence
may be more readily attainable for the patient.
Summary
The findings reviewed above demonstrate that, in addition to the rewarding
effects  of  nicotine,  noxious  effects  of  the  drug  also  likely  influence  the
development  and  persistence  of  the  tobacco  smoking  habit  in  humans.
Specifically, avoidance of the aversive properties of nicotine play a key role in
determining the amounts of nicotine consumed, patterns of consumption, and
hence the magnitude by which nicotine induces neuroplasticity in addiction-
relevant brain reinforcement circuits. Habenula-interpedunular glutamatergic
28
transmission  and  aspects  of  mesoaccumbens  dopamine,  acetylcholine  and
opioid transmission appear to regulate the aversive effects of nicotine,  and
thereby control  avoidance of  the drug.  Moreover,  allelic  variation  in  genes
highly expressed in the aversion-related circuitries, in particular the CHRNA5
gene  that  encodes  the  5  nAChR  subunit,  can  influence  vulnerability  to
tobacco  dependence  in  humans,  highlighting  the  importance  of  nicotine
aversion in controlling vulnerability to addiction. Much work still  remains to
precisely understand how the aversive effects of nicotine are encoded in the
brain, and how aversion-related circuits may interact with reward circuits to
control  nicotine  intake.  Nevertheless,  the  available  data  support  the
interesting possibility  that amplifying the noxious properties of  nicotine via
small  molecule drugs may serve as a novel  strategy to develop efficacious
smoking cessation agents.
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Figure legends:
Allelic variation in the  CHRNA5-CHRNA3-CHRNB4 gene cluster contributes to
vulnerability  to  tobacco  dependence.  (a)  Graphical  representation  of  the
genomic organization of the  CHRNA5-CHRNA3-CHRNB4 nAChR subunit gene
cluster on chromosome 15 (Chr15 q25.1). (b) Mice with null mutation in the 5
subunit  gene  self-administer  more  nicotine  than  wildtype  mice.  Mice  were
responding under a fixed-ratio 5 time-out 20 sec schedule of reinforcement.
(c) Data from panel B were transformed such that the total amount of nicotine
self-administered by wildtype and knockout mice could be examine. Data are
modified with permission from (Fowler et al., 2011).
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